knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 21:35:59 - browse：15835

The U.S. Department of Labor claims in a new lawsuit that a UnitedHealth Group unit illegally rejected emergency room care and urine drug screen claims for thousands of people.

UMR, Inc., a Wisconsin-based third-party administrator owned by UnitedHealth, manages benefits for more than 2,100 employee health plans. The federal government says the company denied ER visits and urine drug screens for years using a process that didn’t meet federal standards for health plans that employers fund themselves, known as self-insured plans. The standards are part of a law called the Employee Retirement Income Security Act, or ERISA.

“I see it as significant because the Department of Labor is actually looking under the hood at the standards and methods that insurers apply when they decide whether or not to approve or deny a claim,” said Colleen Medill, a professor at the University of Nebraska College of Law and nationally recognized legal scholar on ERISA. “They are looking at their process.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Archived: an online chat discussing Ebola, vaccines, and a new epidemic

WSS

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

WHO may add ‘noma' to its list of neglected tropical diseases

Biden's order seeks to regulate AI risk without stifling innovation

Maker of FluMist seeks to allow at

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

focus

knowledge

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Use doctors trained outside the U.S. to ease the physician shortage

Drug repurposing or repositioning? The language matters

Hospitals warn Medicare's drug payment fix is ‘unlawful’

In Memoriam: Notable people who died in 2023

AstraZeneca lung cancer study comes in below expectations

Cancer drug shortages should be causing more outrage

FDA has safety concerns on CRISPR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The pink breast cancer awareness ribbon needs a redesign

explore

The biotech scorecard for Q3: 15 stock

Physician subsidies by hospitals soar in wake of No Surprises Act

STAT wants to know your pick for a great summer read or listen

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

A letter from the executive editor: The 2023 STATUS List

Skip the lead apron during X

focus

entertainment

knowledge

entertainment